ANTITUMOR ACTIVITY OF PI3K ANTAGONIST AEZS126*IN MODELS OF TRIPLE NEGATIVE BREAST CANCER

被引：0
|
作者：
Engel, J. B. [1 ]
Schmidt, H. [1 ]
Haeussler, S. [1 ]
Diessner, J. [1 ]
Hahne, J. [1 ]
Meyer, S. [1 ]
Wischhusen, J. [1 ]
Dietl, J. [1 ]
Hoenig, A. [1 ]
机构：
[1] Univ Wurzburg, Dept Obstet & Gynecol, Wurzburg, Germany
来源：
ANTICANCER RESEARCH | 2011年 / 31卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1967 / 1968
页数：2
相关论文
共 50 条
  • [41] Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
    Solzak, J. P.
    Atale, R.
    Hancock, B.
    Radovich, M.
    CANCER RESEARCH, 2016, 76
  • [42] Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
    Jeffrey P. Solzak
    Rutuja V. Atale
    Bradley A. Hancock
    Anthony L. Sinn
    Karen E. Pollok
    David R. Jones
    Milan Radovich
    npj Breast Cancer, 3
  • [43] Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
    Solzak, Jeffrey P.
    Atale, Rutuja V.
    Hancock, Bradley A.
    Sinn, Anthony L.
    Pollok, Karen E.
    Jones, David R.
    Radovich, Milan
    NPJ BREAST CANCER, 2017, 3
  • [44] Insights into the compensation mechanism behind targeting PI3K and Wnt in triple-negative breast cancer
    Solzak, Jeffrey P.
    Wang, Chao
    Radovich, Milan
    CANCER RESEARCH, 2022, 82 (04)
  • [45] DNA copy number changes in the PI3K signaling pathway genes in triple negative breast cancer
    Oliveira, Marcia C.
    Pereira, Silma R.
    Ribeiro, Enilze M. F.
    Lima, Rubens S.
    Urban, Cicero A.
    Sebastiao, Ana Paula M.
    Marian, Catalin
    Haddad, Bassem R.
    Cavalli, Iglenir J.
    Cavalli, Luciane R.
    CANCER RESEARCH, 2011, 71
  • [46] Novel tumor suppressor regulating the PI3K/AKT pathway in triple negative breast cancer (TNBC)
    Chan, Stefanie
    Smith, Emma
    Monti, Stefano
    Cardamone, M. Dafne
    Perissi, Valentina
    CANCER RESEARCH, 2020, 80 (04)
  • [47] Combined Blockade of PI3K/AKT and EGFR/HER3 Enhances Anti-Tumor Activity in Triple Negative Breast Cancer
    Tao, J.
    Ip, P.
    Auricchio, N.
    Juric, D.
    Yu, M.
    Shyamala, M.
    Kim, P.
    Singh, S.
    Hazra, S.
    Haber, D.
    Scaltriti, M.
    Baselga, J.
    CANCER RESEARCH, 2012, 72
  • [48] Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models
    Rudi, Bao
    Wang, Dagong
    Qu, Hui
    Yin, Ling
    Zifcak, Brian
    DellaRocca, Steven
    Xu, Guang-Xin
    Borek, Mylissa
    Samson, Maria
    Atoyan, Ruzanna
    Poll, Anne
    Wang, Jing
    Zhai, Hai-Xaio
    Lai, Cheng-Jung
    Pepicelli, Carmen
    Cai, Xiong
    Qian, Changgeng
    CANCER RESEARCH, 2012, 72
  • [49] Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers
    Gordon, Vallerie
    Banerji, Shantanu
    CLINICAL CANCER RESEARCH, 2013, 19 (14) : 3738 - 3744
  • [50] Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R
    de Lint, Klaas
    Poell, Jos B.
    Soueidan, Hayssam
    Jastrzebski, Katarzyna
    Rodriguez, Jordi Vidal
    Lieftink, Cor
    Wessels, Lodewyk F. A.
    Beijersbergen, Roderick L.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (07) : 1545 - 1556
12345